Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment
暂无分享,去创建一个
[1] Rainer Fietkau,et al. Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses – Pre-Clinical Evidence and Ongoing Clinical Applications , 2015, Front. Immunol..
[2] A. Ribas. Adaptive Immune Resistance: How Cancer Protects from Immune Attack. , 2015, Cancer discovery.
[3] S. Demaria,et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. , 2015, The Lancet. Oncology.
[4] J. Zavadil,et al. TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. , 2015, Cancer research.
[5] Joe Y. Chang,et al. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. , 2015, Cancer treatment reviews.
[6] H. Kohrt,et al. Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions , 2015, Clinical Cancer Research.
[7] Sean S. Park,et al. PD-1 Restrains Radiotherapy-Induced Abscopal Effect , 2015, Cancer Immunology Research.
[8] H. Ishwaran,et al. Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.
[9] P. Lambin,et al. Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects , 2014, Clinical Cancer Research.
[10] P. Hegde,et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.
[11] R. Weichselbaum,et al. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. , 2014, Immunity.
[12] R. Fietkau,et al. Norm- and hypo-fractionated radiotherapy is capable of activating human dendritic cells , 2014, Journal of immunotoxicology.
[13] I. Stratford,et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. , 2014, Cancer research.
[14] D. Gomez,et al. Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors? , 2014, Cancer Immunology Research.
[15] Mansoor M Ahmed,et al. Unlocking the Combination: Potentiation of Radiation-Induced Antitumor Responses with Immunotherapy , 2014, Radiation research.
[16] N. Agarwal,et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.
[17] P. Ascierto,et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy , 2014, Oncoimmunology.
[18] R. Weichselbaum,et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.
[19] A. Bhatia,et al. Cellular and molecular mechanisms in cancer immune escape: a comprehensive review , 2014, Expert review of clinical immunology.
[20] D. Getnet,et al. Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer model. , 2013, International journal of radiation oncology, biology, physics.
[21] A. Kumari,et al. Turning T cells on: epigenetically enhanced expression of effector T-cell costimulatory molecules on irradiated human tumor cells , 2013, Journal of Immunotherapy for Cancer.
[22] John Wong,et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. , 2013, International journal of radiation oncology, biology, physics.
[23] M. Sznol,et al. Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer , 2013, Clinical Cancer Research.
[24] K. Iwamoto,et al. Maximizing tumor immunity with fractionated radiation. , 2012, International journal of radiation oncology, biology, physics.
[25] R. Johnstone,et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. , 2012, Cancer research.
[26] W. Urba,et al. Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2—Tumor and Immunological Responses , 2012, Science Translational Medicine.
[27] Dong Yu,et al. An In Situ Autologous Tumor Vaccination with Combined Radiation Therapy and TLR9 Agonist Therapy , 2012, PloS one.
[28] R. Hannan,et al. Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer , 2012, Cancer Immunology, Immunotherapy.
[29] Jedd D. Wolchok,et al. Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.
[30] J. Hodge,et al. Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation. , 2012, Cancer biotherapy & radiopharmaceuticals.
[31] H. Nagawa,et al. Intratumoral injection of interleukin‐2 augments the local and abscopal effects of radiotherapy in murine rectal cancer , 2011, Cancer science.
[32] Axel Hoos,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.
[33] L. Tenenbaum,et al. Development of a successful antitumor therapeutic model combining in vivo dendritic cell vaccination with tumor irradiation and intratumoral GM-CSF delivery , 2011, Cancer Immunology, Immunotherapy.
[34] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[35] H. Shirato,et al. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. , 2010, Cancer research.
[36] Xuefang Cao. Regulatory T cells and immune tolerance to tumors , 2010, Immunologic research.
[37] N. Kawashima,et al. Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody , 2009, Clinical Cancer Research.
[38] R. Weichselbaum,et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. , 2009, Blood.
[39] H. Shirato,et al. Combination immunotherapy with radiation and CpG‐based tumor vaccination for the eradication of radio‐ and immuno‐resistant lung carcinoma cells , 2009, Cancer science.
[40] S. Steinberg,et al. High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma , 2008, Cancer.
[41] K. Camphausen,et al. The Use of Chelated Radionuclide (Samarium-153-Ethylenediaminetetramethylenephosphonate) to Modulate Phenotype of Tumor Cells and Enhance T Cell–Mediated Killing , 2008, Clinical Cancer Research.
[42] S. Gerber,et al. Radiation-Induced IFN-γ Production within the Tumor Microenvironment Influences Antitumor Immunity1 , 2008, The Journal of Immunology.
[43] K. Camphausen,et al. Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects , 2008, Cancer Immunology and Immunotherapy.
[44] M. Nishimura,et al. Combination tumor immunotherapy with radiotherapy and Th1 cell therapy against murine lung carcinoma , 2007, Clinical & Experimental Metastasis.
[45] James B. Mitchell,et al. Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. , 2007, Cancer research.
[46] B. Nelson,et al. Standard Treatments Induce Antigen-Specific Immune Responses in Prostate Cancer , 2007, Clinical Cancer Research.
[47] W. Mendenhall,et al. Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. , 2006, International journal of radiation oncology, biology, physics.
[48] T. Waldmann. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design , 2006, Nature Reviews Immunology.
[49] K. Camphausen,et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy , 2006, The Journal of experimental medicine.
[50] S. Rosenberg,et al. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. , 2006, Blood.
[51] I. Lax,et al. Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma , 2006, Acta oncologica.
[52] M. Gordon. Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma , 2006 .
[53] Robert C. Rose,et al. Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor1 , 2005, The Journal of Immunology.
[54] N. Kawashima,et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[55] L. Milas,et al. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[56] C. N. Coleman,et al. External Beam Radiation of Tumors Alters Phenotype of Tumor Cells to Render Them Susceptible to Vaccine-Mediated T-Cell Killing , 2004, Cancer Research.
[57] Sun-Hee Kim,et al. Direct injection of immature dendritic cells into irradiated tumor induces efficient antitumor immunity , 2004, International journal of cancer.
[58] N. Kawashima,et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. , 2004, International journal of radiation oncology, biology, physics.
[59] Fumito Ito,et al. Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. , 2003, Cancer research.
[60] S. Steinberg,et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] K. Camphausen,et al. Radiation abscopal antitumor effect is mediated through p53. , 2003, Cancer research.
[62] Luca Scorrano,et al. A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. , 2002, Cancer cell.
[63] C. Chiang,et al. Combining radiation therapy with interleukin-3 gene immunotherapy , 2000, Cancer Gene Therapy.
[64] B. Vikram,et al. Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. , 1999, Cancer research.
[65] K. Konoeda. [Therapeutic efficacy of pre-operative radiotherapy on breast carcinoma: in special reference to its abscopal effect on metastatic lymph-nodes]. , 1990, Nihon Gan Chiryo Gakkai shi.
[66] R. Rees,et al. Interleukin-2 and cancer therapy. , 1990, Cancer cells.
[67] J. Le Bourgeois,et al. [Whole body irradiation]. , 1989, Pathologie-biologie.
[68] Mole Rh. Whole body irradiation; radiobiology or medicine? , 1953 .